人参皂苷Rg3辅助治疗结肠癌临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R735.3+5

基金项目:


Clinical Study on Ginsenoside Rg3 in Adjuvant Therapy of Colon Cancer
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察人参皂苷Rg3 辅助治疗结肠癌的临床疗效。方法:选取89 例Ⅲ期结肠癌患者,按随机数字表法分为观察组45 例和对照组44 例。对照组给予氟尿嘧啶(5-Fu) +亚叶酸钙+奥沙利铂治疗,观察组在对照组基础上给予人参皂苷Rg3治疗。比较2 组短期疗效及治疗前后免疫细胞水平、血管内皮生长因子(VEGF)、p53 表达及生活质量评分。结果:观察组短期总有效率为82.22%,高于对照组59.09%,差异有统计学意义(P<0.05)。治疗前,2 组白细胞介素-2(IL-2)、干扰素-γ(IFN-γ)、肿瘤坏死因子-α(TNF-α)、白细胞介素-4(IL-4)、白细胞介素-6(IL-6) 及白细胞介素-10(IL-10) 水平比较,差异无统计学意义(P>0.05)。治疗后,2 组IL-2、IFN-γ、TNF-α 水平高于治疗前,且观察组高于对照组(P<0.05);2 组IL-4、IL-6 及IL-10 水平低于治疗前,且观察组低于对照组(P<0.05)。治疗前,2 组VEGF 及p53 水平比较,差异无统计学意义(P>0.05)。治疗后,2 组VEGF 及p53 水平低于治疗前,且观察组VEGF 及p53 水平低于对照组,差异有统计学意义(P<0.05)。治疗前,2 组生活质量4 个领域评分比较,差异无统计学意义(P>0.05)。治疗后,2 组生活质量4 个领域评分较治疗前升高,且观察组各项评分高于对照组,差异有统计学意义(P<0.05)。结论:人参皂苷Rg3 辅助治疗结肠癌患者的疗效确切,有助于促进机体免疫细胞水平的稳定,调节VEGF、p53 水平,提高患者生活质量。

    Abstract:

    Abstract:Objective:To observe the clinical effect of ginsenoside Rg3 in adjuvant therapy of colon cancer. Methods:A total of 89 cases of patients with stage III colon cancer were divided into the observation group and the control group according to the random number table method,45 and 44 cases in each group. The control group was treated with fluorouracil (5-FU),calcium folinate,and oxaliplatin,and the observation group was additionally treated with ginsenoside Rg3 based on the treatment of the control group. Short- term curative effect was compared between the two groups. Before and after treatment,the level of immune cells,vascular endothelial growth factor(VEGF),the expression of p53,and the score of quality of life were compared between the two groups. Results: The short- term curative effect was 82.22% in the observation group, higher than that of 59.09% in the control group, the difference being significant(P<0.05). Before treatment, when compared levels of interleukin- 2(IL- 2), interferon- γ(IFN- γ), tumor necrosis factor- α(TNF- α), interleukin-4(IL-4),interleukin-6(IL-6),and interleukin-10(IL-10) between the two groups,there was no significance in the difference(P>0.05). After treatment, levels of IL- 2, IFN- γ, and TNF- α in the two groups were higher than those before treatment,and the three levels above in the observation group were higher than those in the control group(P<0.05); levels of IL- 4, IL- 6, and IL- 10 in the two groups were lower than those before treatment, and the three levels in the observation group were lower than those in the control group(P<0.05). Before treatment,there was no significant difference being found in the comparison of levels of VEGF and p53 between the two groups(P>0.05). After treatment,levels of VEGF and p53 in the two groups were lower than those before treatment,and the two levels in the observation group were lower than those in the control group,the difference being significant(P<0.05). Before treatment,when compared scores of four domains of quality of life between the two groups, there was no significance being found in the difference(P>0.05). After treatment, scores of four domains of quality of life in the two groups were increased when compared with those before treatment,and each score in the observation group was higher than that in the control group,the difference being significant(P<0.05). Conclusion:Ginsenoside Rg3 has a defined curative effect in adjuvant therapy of colon cancer,which can promote the stability of levels of immune cells,regulate levels of VEGF and p53,and improve the quality of life.

    参考文献
    相似文献
    引证文献
引用本文

朱鸣,高山.人参皂苷Rg3辅助治疗结肠癌临床研究[J].新中医,2021,53(19):156-159

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-10-09
  • 出版日期:
文章二维码